Ignite Creation Date:
2024-05-06 @ 2:56 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04478708
Status:
COMPLETED
Last Update Posted:
2024-05-13
First Post:
2020-07-16
Brief Title:
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 1 Randomized Double-blind Placebo-controlled Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AMG 133 in Subjects With Obesity
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None